Week in Review: Haohai Biological Schedules $305 Million Hong Kong IPO

Shanghai Haohai Biological Technology, which makes absorbable biomedical medical devices, will raise as much as $305 million in a Hong Kong IPO; WuXi PharmaTech invested $15 million in DNAnexus of Boston and will place its genomic services on the DNAnexus cloud-based platform; Kunming Biomed of China signed up BTS Research of San Diego to import and distribute KBI’s non-human primates in the western United States; Aliyun, an Alibaba subsidiary, will work with two other China companies to build China's first cloud hospital; the ChinaBio® Partnering Forum 2015 brought a record 858 internationally-focused life science executives and investors to Shanghai on April 15-16; the CBPF discussed innovation in drug development, though individual companies seemed to have different ideas of what the concept means; a Plenary Panel at the CBPF concluded that economics force biologic companies to develop both innovative biotech drugs and biosimilars; Uni-Bio Science Group of Hong Kong filed for China approval of Uni-PTH, the company's proprietary treatment for osteoporosis; and PPD, the US-based CRO, opened a central laboratory in Shanghai at the Shanghai Clinical Research Center. More details.... Stock Symbols: (NYSE: WX) (NYSE: BABA) (HK: 690) Share this with colleagues: // //